Uniphar’s (UPR) Buy Rating Reiterated at Shore Capital

Shore Capital reaffirmed their buy rating on shares of Uniphar (LON:UPRFree Report) in a research report released on Tuesday, Marketbeat.com reports.

Uniphar Stock Performance

Shares of UPR stock opened at GBX 195 ($2.42) on Tuesday. The firm has a market capitalization of £532.39 million, a price-to-earnings ratio of 1,392.86 and a beta of 0.75. The business has a 50 day simple moving average of GBX 175.68 and a 200 day simple moving average of GBX 198.70. Uniphar has a 12-month low of GBX 163 ($2.02) and a 12-month high of GBX 256 ($3.18). The company has a debt-to-equity ratio of 119.43, a current ratio of 0.90 and a quick ratio of 0.60.

Uniphar Company Profile

(Get Free Report)

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.

Featured Articles

Receive News & Ratings for Uniphar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniphar and related companies with MarketBeat.com's FREE daily email newsletter.